Doloromics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Doloromics was a Dallas, Texas-based precision neuropharmaceutical company spun out of a university in 2020. It built a proprietary drug-discovery and validation platform called DOLOReS, which used single-cell transcriptomics, proteomics, and computational modeling of human sensory tissue to identify novel therapeutic targets for chronic pain conditions such as migraine and fibromyalgia.
02 / Doloromics FAILURE REASONS
Failure reasons
Doloromics shut down in March 2025 while still at the pre-clinical stage. No public statement of specific failure reasons was found; as an early-stage therapeutics company, it had not yet advanced any drug candidate into clinical trials, and its lead asset was only approaching an investigational new drug application at the time operations ended.
03 / EVENT HISTORY
Events in the structured record
- Founded
Doloromics was founded as a university spin-out in Dallas, Texas, to develop precision therapeutics for chronic pain.
- Accelerator selection
The company was selected for the Illumina Accelerator's funding cycle.
- Seed funding
Doloromics raised an early-stage venture round and a seed round, with Mayfield Fund among its investors.
- Pipeline progress
Co-founder and chief scientific officer Jackson Brougher described the company's lead asset as approaching an IND (investigational new drug application), with plans to partner with larger pharmaceutical companies rather than run late-stage trials itself.
- Shut down
The company shut down in March 2025 and is listed as out of business.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
The company shut down in March 2025 and is recorded as out of business.
- 02
No public disclosure of remaining assets, liabilities, or investor recoveries was found.